ES2606627T8 - Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis - Google Patents

Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis Download PDF

Info

Publication number: ES2606627T8
Authority: ES; Spain
Prior art keywords: neoangiogenesis; antibodies; treatment; specific anti; eye disorders
Prior art date: 2010-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES11728594.0T

Other languages

English (en)

Other versions

ES2606627T3 (es

Inventor

Philippe Le Bouteiller

Armand Bensussan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Elsalys Biotech

Institut National de la Sante et de la Recherche Medicale INSERM

Original Assignee

Elsalys Biotech

Institut National de la Sante et de la Recherche Medicale INSERM

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-28

Filing date

2011-05-27

Publication date

2017-06-09

2011-05-27 Application filed by Elsalys Biotech, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Elsalys Biotech

2017-03-24 Application granted granted Critical

2017-03-24 Publication of ES2606627T3 publication Critical patent/ES2606627T3/es

2017-06-09 Publication of ES2606627T8 publication Critical patent/ES2606627T8/es

Status Active legal-status Critical Current

2031-05-27 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

ES11728594.0T 2010-05-28 2011-05-27 Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis Active ES2606627T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US34927110P	2010-05-28	2010-05-28
US349271P		2010-05-28
PCT/EP2011/058777 WO2011147984A1 (en)	2010-05-28	2011-05-27	Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

Publications (2)

Publication Number	Publication Date
ES2606627T3 ES2606627T3 (es)	2017-03-24
ES2606627T8 true ES2606627T8 (es)	2017-06-09

Family

ID=44276158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES11728594.0T Active ES2606627T3 (es)	2010-05-28	2011-05-27	Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis

Country Status (11)

Country	Link
US (2)	US9045544B2 (es)
EP (1)	EP2575881B1 (es)
JP (1)	JP5990511B2 (es)
KR (1)	KR101847572B1 (es)
CN (2)	CN107648605A (es)
BR (1)	BR112012030318A2 (es)
CA (1)	CA2796312C (es)
DK (1)	DK2575881T3 (es)
ES (1)	ES2606627T3 (es)
PL (1)	PL2575881T3 (es)
WO (1)	WO2011147984A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10561707B2 (en) *	2013-09-08	2020-02-18	Technion Research And Development Foundation Ltd.	Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3145532A4 (en) *	2014-05-02	2018-02-21	Mayo Foundation for Medical Education and Research	Individualized treatment of eye disease
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
CA3080270A1 (en) *	2016-10-25	2018-05-03	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Monoclonal antibodies binding to the cd160 transmembrane isoform
FR3061716B1 (fr) *	2017-01-06	2019-05-17	Elsalys Biotech	Nouveaux composes ciblant le cd160 humain
SG11202001595SA (en) *	2017-08-31	2020-03-30	Singapore Health Serv Pte Ltd	Angio-3 for treatment of retinal angiogenic diseases
EP3758737A4 (en)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
US20230073132A1 (en) *	2019-12-31	2023-03-09	Medstar Health, Inc.	Anti-cd 160 binding molecules for treating diseases
CN116368154A (zh)	2020-10-08	2023-06-30	阿菲姆德股份有限公司	三特异性结合剂
CA3216098A1 (en)	2021-07-30	2023-02-02	Uwe Reusch	Duplexbodies
IL319568A (en)	2022-09-15	2025-05-01	Avidicure Ip B V	Multispecific antigen-binding proteins for NK cell stimulation and their uses
WO2025191133A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
ATE207080T1 (de)	1991-11-25	2001-11-15	Enzon Inc	Multivalente antigen-bindende proteine
ATE187494T1 (de)	1992-12-11	1999-12-15	Dow Chemical Co	Multivalente einkettige antikörper
AU5253898A (en)	1996-11-12	1998-06-03	Dana-Farber Cancer Institute	Recombinant by55 and nucleic acids encoding same
US6884879B1 (en) *	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
FR2794977B1 (fr) *	1999-06-18	2003-10-31	Commissariat Energie Atomique	Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
EP1626059A1 (en) *	2004-08-09	2006-02-15	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
EP1981520A2 (en) *	2006-01-30	2008-10-22	(OSI) Eyetech, Inc.	Combination therapy for the treatment of neovascular disorders
AR062239A1 (es) *	2007-08-07	2008-10-22	Civil De Estudios Superiores A	Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal

2011
- 2011-05-27 JP JP2013511702A patent/JP5990511B2/ja not_active Expired - Fee Related
- 2011-05-27 US US13/697,699 patent/US9045544B2/en active Active
- 2011-05-27 KR KR1020127034345A patent/KR101847572B1/ko not_active Expired - Fee Related
- 2011-05-27 EP EP11728594.0A patent/EP2575881B1/en active Active
- 2011-05-27 CA CA2796312A patent/CA2796312C/en active Active
- 2011-05-27 CN CN201710912201.2A patent/CN107648605A/zh active Pending
- 2011-05-27 DK DK11728594.0T patent/DK2575881T3/en active
- 2011-05-27 ES ES11728594.0T patent/ES2606627T3/es active Active
- 2011-05-27 CN CN201180024138XA patent/CN102892432A/zh active Pending
- 2011-05-27 WO PCT/EP2011/058777 patent/WO2011147984A1/en not_active Ceased
- 2011-05-27 BR BR112012030318A patent/BR112012030318A2/pt not_active Application Discontinuation
- 2011-05-27 PL PL11728594T patent/PL2575881T3/pl unknown
2015
- 2015-06-02 US US14/728,253 patent/US10208124B2/en active Active

Also Published As

Publication number	Publication date
CA2796312C (en)	2020-11-03
ES2606627T3 (es)	2017-03-24
KR20130086548A (ko)	2013-08-02
BR112012030318A2 (pt)	2017-06-20
CN102892432A (zh)	2013-01-23
KR101847572B1 (ko)	2018-05-24
US20150344572A1 (en)	2015-12-03
DK2575881T3 (en)	2017-01-09
WO2011147984A1 (en)	2011-12-01
EP2575881B1 (en)	2016-09-14
US10208124B2 (en)	2019-02-19
CN107648605A (zh)	2018-02-02
US9045544B2 (en)	2015-06-02
JP2013528607A (ja)	2013-07-11
CA2796312A1 (en)	2011-12-01
JP5990511B2 (ja)	2016-09-14
US20130122006A1 (en)	2013-05-16
EP2575881A1 (en)	2013-04-10
PL2575881T3 (pl)	2018-06-29

Publication	Publication Date	Title
ES2606627T8 (es)	2017-06-09	Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
LTPA2020510I1 (lt)	2020-07-10	Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
PT2760475T (pt)	2018-10-25	Proteínas de fusão para o tratamento de distúrbios metabólicos
PT2919796T (pt)	2021-06-02	Utilização de akkermansia para o tratamento de distúrbios metabólicos
IL229582B (en)	2020-06-30	Anti-kir antibodies for the treatment of inflammatory disorders
CO6940432A2 (es)	2014-05-09	Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
LT2558105T (lt)	2020-02-10	Bardoksolono metilas, skirtas nutukimo gydymui
PL2686347T3 (pl)	2018-10-31	Przeciwciała przeciwko CD70
CO6821964A2 (es)	2013-12-31	Compuestos para el tratamiento de la adicción
DE112011105572A5 (de)	2014-06-12	Therapeutischer Gehtrainer
CO6880069A2 (es)	2014-02-28	Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
BR112014013843A2 (pt)	2017-07-04	uso de dispositivos para o tratamento de doenças neurológicas
CO6970598A2 (es)	2014-06-13	Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares
PT2768859T (pt)	2018-05-23	Antagonistas de il17c para o tratamento de desordens inflamatórias
BR112013031117A2 (pt)	2018-06-19	scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
IL228030B (en)	2018-01-31	Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia
BRPI1009783A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos.
IL230960A0 (en)	2014-03-31	A device for the treatment of eye disease
CO6821965A2 (es)	2013-12-31	1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
HRP20260138T1 (hr)	2026-04-10	Postupak priprave 2,3,3,3-tetrafluoropropena
IL230959A0 (en)	2014-03-31	A device for the treatment of eye disease
BR112013015048A2 (pt)	2016-07-19	composição para o tratamento de distúrbios metabólicos
BRPI0909659A2 (pt)	2015-09-22	tratamento para distúrbios relacionados oculares
ES2859675T8 (es)	2022-01-17	Sensor y procedimiento para operar el sensor
ES1073254Y (es)	2011-02-28	Electrovalvula para la regulacion de fluidos